Amgen's sales, profits rise in Q2

THOUSAND OAKS, Calif. Biotech company Amgen had $3.8 billion in sales and $1.33 billion in profits during second quarter 2010, according to an earnings report.

Those numbers compared with $3.71 billion in sales and $1.31 billion in profits in second quarter 2009.

Total product sales decreased by 1% during the quarter to $3.61 billion, compared with $3.63 billion in second quarter 2009. U.S. sales were $2.79 billion, a 2% decrease from $2.83 billion in second quarter 2009. In terms of individual products, global sales of the anemia drug Aranesp (darbepoetin alfa) decreased from $693 million to $603 million, including a 21% decrease in U.S. sales of the drug. Sales of the anemia treatment Epogen (epoetin alfa) increased from $638 million to $657 million, while combined sales of the anti-infective drugs Neupogen (filgrastim) and Neulasta (pegfilgrastim) increased from $1.16 billion to $1.17 billion. Sales of the autoimmune disease treatment Enbrel (etanercept) decreased from $899 million to $877 million. Meanwhile, sales of the cancer drug Vectibix (panitumumab), recently launched in the United States, increased from $56 million to $72 million.